

# Press Release



## **ASKA Pharmaceutical Terminates Joint Research and Development Agreement with RIBOMIC**

---

**TOKYO, September 30, 2022** - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi), announced that joint research and development agreement between ASKA and RIBOMIC Inc. (Head Office: Minato-ku, Tokyo/ President and CEO: Yoshikazu Nakamura, hereinafter “RIBOMIC”) was terminated due to the expiration of the research step stipulated in the agreement. This agreement was signed by ASKA and RIBOMIC in February 2021 for drug discovery research and development targeting specific hormone receptors.

The impact of this matter on the Company's financial results for the fiscal year ending March 31, 2023 will be immaterial.

---

### **Media Contacts**

ASKA Pharmaceutical Holdings Co., Ltd.  
Corporate Planning Department  
Tel: +81-3-5484-8366  
Email: [kouhou@aska-pharma.co.jp](mailto:kouhou@aska-pharma.co.jp)